NASDAQ$SKIN
SkinHealth Systems Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Achieved record sales driven by strong performance in Delivery Systems and accelerated Consumables trends, alongside strategic initiatives and brand building programs.
The Beauty Health Company reported exceptional second-quarter results with a 371.2% increase in net sales compared to Q2 2020, driven by strong performance in both Delivery Systems and Consumables. The company is raising its full-year sales guidance to $230 million to $240 million.
- Net sales increased by 371.2% to $66.5 million compared to Q2 2020.
- Delivery System net sales increased to $34.9 million, while Consumables net sales increased to $31.6 million.
- Gross margin increased to 71.0% compared to 30.3% in Q2 2020.
- Adjusted EBITDA was $11.4 million, compared to an adjusted EBITDA loss of $1.1 million in Q2 2020.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$66.5M
Revenue by segment
Beauty Health · $66.5M total across 2 segments · Q2 2021
- Delivery Systems$34.9M+481.7%52.5%
- Consumables$31.6M+290.1%47.5%
Forward guidance
BeautyHealth is raising its fiscal 2021 net sales guidance to $230 million to $240 million and expects adjusted EBITDA of approximately $25 million.
Tailwinds
- Raising fiscal 2021 net sales guidance to $230 million to $240 million.
- Expects adjusted EBITDA of approximately $25 million.
- Anticipates up to $15 million of capital expenditures.
- Assumes a largely reopened global market.
- Reinvesting in global infrastructure scaling for future growth.
Headwinds
- Achievement of anticipated results is subject to risks and uncertainties.
- Cautious of potential risk for further market closures or other restrictive measures from new COVID-19 strains.
- Uneven global rollout and adoption of the vaccines may impact results.
- Outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment.
- Outlook does not take into account any unannounced acquisitions, dispositions, or financings during 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro